β-Amyloid and Neprilysin Computational Studies Identify Critical Residues Implicated in Binding Specificity

The zinc metalloprotease neprilysin (NEP) promiscuously degrades small bioactive peptides. NEP is among a select group of metalloenzymes that degrade the amyloid beta-peptide (Aβ) in vivo and in situ. Since accumulation of neurotoxic Aβ aggregates in the brain appears to be a causative agent in the pathophysiology of Alzheimer's disease (AD), increased clearance of Aβ resulting from overexpression of NEP exhibits therapeutic potential for AD. However, higher NEP peptidase activity may be harmful without an increased specificity for Aβ over other competing substrates. Crystal structures of NEP-inhibitor complexes and their characterization have highlighted potential amino acid interactions involved in substrate binding and are used as templates to guide our methodology in docking Aβ in NEP. Results from protein-ligand docking calculations predict S2' subsite residues Arg 102 and Arg 110 of NEP participate in specific interactions with Aβ. These interactions provide insight into developing NEP specificity for Aβ.

[1]  D. Teplow,et al.  Structural and kinetic features of amyloid beta-protein fibrillogenesis. , 1998, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[2]  D. Selkoe,et al.  Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. , 2003, Annual review of pharmacology and toxicology.

[3]  F. Diederich,et al.  Second-Generation Inhibitors for the Metalloprotease Neprilysin Based on Bicyclic Heteroaromatic Scaffolds: Synthesis, Biological Activity, and X-ray Crystal Structure Analysis , 2005 .

[4]  M. Citron,et al.  Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.

[5]  A. LeBlanc,et al.  Selective cytotoxicity of intracellular amyloid β peptide1–42 through p53 and Bax in cultured primary human neurons , 2002, The Journal of cell biology.

[6]  L. Hersh,et al.  Insulysin Hydrolyzes Amyloid β Peptides to Products That Are Neither Neurotoxic Nor Deposit on Amyloid Plaques , 2000, The Journal of Neuroscience.

[7]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[8]  P. Coric,et al.  Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities. , 2000, Journal of medicinal chemistry.

[9]  S. Love,et al.  A&bgr;-Degrading Enzymes: Potential for Treatment of Alzheimer Disease , 2011, Journal of neuropathology and experimental neurology.

[10]  N. Belyaev,et al.  Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. , 2008, Current Alzheimer research.

[11]  T. Iwatsubo,et al.  Neprilysin Degrades Both Amyloid β Peptides 1–40 and 1–42 Most Rapidly and Efficiently among Thiorphan- and Phosphoramidon-sensitive Endopeptidases* , 2001, The Journal of Biological Chemistry.

[12]  L. Serpell,et al.  Molecular structure of a fibrillar Alzheimer's A beta fragment. , 2000, Biochemistry.

[13]  L. Hersh,et al.  Circulating neprilysin clears brain amyloid , 2010, Molecular and Cellular Neuroscience.

[14]  Bethany M. Wootton,et al.  The Acceptability of Internet-Based Treatment and Characteristics of an Adult Sample with Obsessive Compulsive Disorder: An Internet Survey , 2011, PloS one.

[15]  L. Hersh,et al.  Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  Dan S. Tawfik,et al.  The 'evolvability' of promiscuous protein functions , 2005, Nature Genetics.

[17]  L. Hersh,et al.  Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer's disease , 2009, Journal of neuroscience research.

[18]  Judianne Davis,et al.  Structural conversion of neurotoxic amyloid-β(1–42) oligomers to fibrils , 2010, Nature Structural &Molecular Biology.

[19]  B. Matthews,et al.  Thiorphan and retro-thiorphan display equivalent interactions when bound to crystalline thermolysin. , 1989, Biochemistry.

[20]  L. Hersh,et al.  Neprilysin and amyloid beta peptide degradation. , 2008, Current Alzheimer research.

[21]  S. Howell,et al.  Neutral endopeptidase can hydrolyze β-amyloid(1–40) but shows no effect on β-amyloid precursor protein metabolism , 1995, Peptides.

[22]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[23]  T. Saido,et al.  Metabolic Regulation of Brain Aβ by Neprilysin , 2001, Science.

[24]  L. Hersh,et al.  Active Site Mutations Change the Cleavage Specificity of Neprilysin , 2012, PloS one.

[25]  S. Manzetti Computer modeling and nanosecond simulation of the enzyme–substrate complex of the common lymphoblastic leukemia antigen (neprilysin) indicates shared residues at the primary specificity pocket (S1') with matrix metalloproteases , 2003, Journal of molecular modeling.

[26]  B. Roques,et al.  Evidence that Asn542 of neprilysin (EC 3.4.24.11) is involved in binding of the P2' residue of substrates and inhibitors. , 1995, The Biochemical journal.

[27]  Nikos Dimitropoulos,et al.  A Computational Approach to the Study of the Binding Mode of Dual ACE/NEP Inhibitors , 2010, J. Chem. Inf. Model..

[28]  T. Saido,et al.  Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.

[29]  E. Masliah,et al.  Peripheral Delivery of a CNS Targeted, Metalo-Protease Reduces Aβ Toxicity in a Mouse Model of Alzheimer's Disease , 2011, PloS one.

[30]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[31]  E Harper,et al.  On the size of the active site in proteases: pronase. , 1972, Biochemical and biophysical research communications.

[32]  I. Hamley The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. , 2012, Chemical reviews.

[33]  M. Fournié-Zaluski,et al.  Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. , 1993, Pharmacological reviews.

[34]  I. Verma,et al.  Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. , 2008, The American journal of pathology.

[35]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[36]  H. Mizukami,et al.  Presynaptic Localization of Neprilysin Contributes to Efficient Clearance of Amyloid-β Peptide in Mouse Brain , 2004, The Journal of Neuroscience.

[37]  S. Love,et al.  Changes with Age in the Activities of β‐Secretase and the Aβ‐Degrading Enzymes Neprilysin, Insulin‐Degrading Enzyme and Angiotensin‐Converting Enzyme , 2010, Brain pathology.

[38]  D. Dickson,et al.  Expression and functional profiling of neprilysin, insulin‐degrading enzyme, and endothelin‐converting enzyme in prospectively studied elderly and Alzheimer’s brain , 2010, Journal of neurochemistry.

[39]  M. Fournié-Zaluski,et al.  Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Araz Jakalian,et al.  Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: I. Method , 2000 .

[41]  L. Hersh,et al.  Analysis of the importance of arginine 102 in neutral endopeptidase (enkephalinase) catalysis. , 1992, The Journal of biological chemistry.

[42]  Dominic M. Walsh,et al.  Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.

[43]  H. Huang,et al.  The correlation between neurotoxicity, aggregative ability and secondary structure studied by sequence truncated Aβ peptides , 2007, FEBS letters.

[44]  D. Selkoe,et al.  Aggregation and catabolism of disease-associated intra-Aβ mutations: reduced proteolysis of AβA21G by neprilysin , 2008, Neurobiology of Disease.

[45]  B. Roques,et al.  Structural analysis of neprilysin with various specific and potent inhibitors. , 2004, Acta crystallographica. Section D, Biological crystallography.

[46]  M. Cascio,et al.  Neprilysin Inhibitors Provide Insight into its Specificity and Therapeutic Potential , 2014 .

[47]  D. Selkoe,et al.  Kinetics of Amyloid β-Protein Degradation Determined by Novel Fluorescence- and Fluorescence Polarization-based Assays* , 2003, Journal of Biological Chemistry.

[48]  T. Saido,et al.  Reply to: 'Clearance of amyloid β-peptide from brain: transport or metabolism?' , 2000, Nature Medicine.

[49]  C. Oefner,et al.  Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV. , 2007, Acta crystallographica. Section D, Biological crystallography.

[50]  E. Capetillo-Zarate,et al.  Impaired β-Amyloid Secretion in Alzheimer's Disease Pathogenesis , 2011, The Journal of Neuroscience.

[51]  I. Hakker,et al.  Overexpression of Neprilysin Reduces Alzheimer Amyloid-β42 (Aβ42)-induced Neuron Loss and Intraneuronal Aβ42 Deposits but Causes a Reduction in cAMP-responsive Element-binding Protein-mediated Transcription, Age-dependent Axon Pathology, and Premature Death in Drosophila* , 2008, Journal of Biological Chemistry.

[52]  D. Selkoe,et al.  Reducing Amyloid Plaque Burden via Ex Vivo Gene Delivery of an Aβ-Degrading Protease: A Novel Therapeutic Approach to Alzheimer Disease , 2007, PLoS medicine.

[53]  D. Owen,et al.  Synthesis and evaluation of heteroarylalanine diacids as potent and selective neutral endopeptidase inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[54]  F. Gage,et al.  Neprilysin regulates amyloid β peptide levels , 2007, Journal of Molecular Neuroscience.

[55]  Y. Lyubchenko,et al.  Residues 17–20 and 30–35 of beta‐amyloid play critical roles in aggregation , 2004, Journal of neuroscience research.

[56]  T. Saido,et al.  Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Aβ to physiologically relevant proteolytic degradation , 2003, The Lancet.

[57]  B. de Strooper Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. , 2010, Physiological reviews.

[58]  Kenjiro Ono,et al.  Structure–neurotoxicity relationships of amyloid β-protein oligomers , 2009, Proceedings of the National Academy of Sciences.

[59]  Paul Labute,et al.  Variability in docking success rates due to dataset preparation , 2012, Journal of Computer-Aided Molecular Design.

[60]  A three-dimensional construction of the active site (region 507-749) of human neutral endopeptidase (EC.3.4.24.11). , 1999, Protein engineering.

[61]  D. Coates,et al.  The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[62]  Heike Wulff,et al.  Amyloid-β Protein Oligomer at Low Nanomolar Concentrations Activates Microglia and Induces Microglial Neurotoxicity* , 2010, The Journal of Biological Chemistry.

[63]  Lars Olsen,et al.  Binding affinities in the SAMPL3 trypsin and host–guest blind tests estimated with the MM/PBSA and LIE methods , 2012, Journal of Computer-Aided Molecular Design.

[64]  L. Serpell,et al.  Molecular Structure of a Fibrillar Alzheimer's Aβ Fragment† , 2000 .

[65]  F. Liu,et al.  A novel system for in vivo neprilysin gene delivery using a syringe electrode , 2010, Journal of Neuroscience Methods.

[66]  M. Goedert,et al.  A Century of Alzheimer's Disease , 2006, Science.

[67]  Immunology and immunotherapy of Alzheimer's disease , 2006, Nature Reviews Immunology.

[68]  K. Tanzawa,et al.  Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[69]  B. Strooper Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process , 2010 .

[70]  A. D'Ursi,et al.  Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. , 2002, European journal of biochemistry.

[71]  F. Winkler,et al.  Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. , 2000, Journal of molecular biology.

[72]  B. Roques,et al.  Differences in the structural requirements for selective interaction with neutral metalloendopeptidase (enkephalinase) or angiotensin-converting enzyme. Molecular investigation by use of new thiol inhibitors. , 1984, European journal of biochemistry.

[73]  S. Howell,et al.  Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. , 1995, Peptides.

[74]  Evidence by site-directed mutagenesis that arginine 203 of thermolysin and arginine 717 of neprilysin (neutral endopeptidase) play equivalent critical roles in substrate hydrolysis and inhibitor binding. , 1997, Biochemistry.

[75]  F. Gage,et al.  Neprilysin regulates amyloid Beta peptide levels. , 2004, Journal of molecular neuroscience : MN.